[{"id":"vista-pe1","name":"Change in body weight from baseline at Week 26","type":"PRIMARY","unit":"%","results":[{"arm":"Summary","value":"Met primary endpoint (specific % not yet disclosed)","p_value":null}],"timepoint":"Week 26","description":"Percent change in body weight from baseline. This measures how much weight participants lose on elecoglipron vs placebo over 26 weeks."},{"id":"vista-pe2","name":"Proportion achieving ≥5% weight loss at Week 26","type":"PRIMARY","unit":"%","results":[{"arm":"Summary","value":"Met primary endpoint (specific % not yet disclosed)","p_value":null}],"timepoint":"Week 26","description":"Responder rate — percentage of patients who lost at least 5% of their starting weight. A 5% threshold is the minimum considered clinically meaningful."}]

OPEN QUESTIONS: 1. What are the specific weight loss percentages by dose? (ADA June 2026) 2. What doses will be taken forward to Phase 3? 3. How does GI tolerability compare to orforglipron? 4. What is the discontinuation rate? INVESTMENT IMPLICATIONS: - Competitive with orforglipron (≥12% WL): Validates AZN obesity franchise, stock positive - Inferior to orforglipron (<10% WL): Questions program viability given LLY head start - No food restriction is a real differentiator for patient compliance Source: ClinicalTrials.gov NCT06579092; AZN Q4:25 earnings Feb 10, 2026

Phase 2b dose-ranging study to identify optimal dose(s) for Phase 3 in obesity/overweight